Jun Jessie Liu, M.S.
Statistical Analyst
Degree
- M.S. in Statistics, Texas A&M University, College Station, TX
Areas of Interest
- Clinical trial design
- Survival analysis
- Haplotype analysis
Publications
Montero AJ, Diaz-Montero M, Liu J, McIntyre BW, Logothetis C, and Tannir N. Multiplex Serum Cytokine Analysis in Patients with Metastatic Renal Cell Carcinoma Treated with Interferon Alpha-2b: Decreases in IL-6 and IL-8 Are Strong Independent Predictors of Clinical Benefit. (In press)
Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Ohinata A, Liu J, Wang X, Eng C. The Use of Systemic Chemotherapy on Neoplasms of Appendiceal Origin: A Single Institution Experience. (In press)
Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, and Kantarjian H. A Prognostic Score For Patients With Lower risk Myelodysplastic Syndrome. Leukemia. 2007 Dec 13 [Epub ahead of print].
Liu J, Kader AK, Shao L, Dinney CP, Wang Y, Gu J, and Wu X. Matrix Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007 May 1; 13(9):2614-20.
Engels EA, Wu X, Gu J, Dong Q, Liu J, and Spitz MR. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007;67(13):6520–7.
Kader AK, Shao L, Dinney CP, Wang Y, Liu J, Gu J, and Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006 Dec 15; 66(24):11644-8.
Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel C, Huang M, Chiang SS, Milas L, Hittelman WN, and Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98.
Abstracts and Presentations
Pettaway CA, Song R, Wang X, Liu J, McDonnell T, Black PC, Prokhorova I, Soto C, Strom S, and Troncoso P. Racial Variation in the Matrix Metalloproteinase: E-cadherin Ratio in Localized Prostate Cancer: Results from A Contemporary Matched Comparative Study. AUA 2008.
Anaya DA, Lahat G, Liu J, Xing Y, Cormier JN, Pisters PW, Lev DC, and Pollock RE. Multifocality drives overall survival in retroperitoneal sarcoma. ASCO 2008.
Pettaway C, Song R, Wang X, Liu J, McDonnell T, Black P, Prokhorova I, Soto C, Strom S, and Troncoso P. Racial Variation in the Matrix Metalloproteinase: E-cadherin Ratio in Localized Prostate Cancer. ASCO 2007.
Engels EA, Wu X, Gu J, Dong Q, Liu J, and Spitz MR. Systematic Evaluation of Genetic Variants in the Inflammation Pathway and Risk of Lung Cancer. AACR 2007.
Yang H, Spitz MR, Liu J, Gu J, Lu C, Stewart DJ, and Wu X. ATM Haplotype-tagging SNPs Predict Non-small Cell Lung Cancer Risk in Caucasians. 2006 AACR.
Kader AK, Shao L, Dinney CP, Wang Y, Liu J, Gu J, Grossman HB, and Wu X. Matrix Metalloproteinase Polymorphisms and Invasive Bladder Cancer Risk. 2006 AACR.
Chang JY, Komaki R, Rohatgi PR, Liu J, Lu C, Stewart D, Allen PK, Cox JD, Spitz MR, and Wu X. P53 polymorphisms predicts poor clinical outcome in non-small cell lung cancer treated by radiotherapy/chemotherapy. ASTRO 2006.
Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel C, Huang M, Chiang SS, Milas L, Hittelman WN, and Ajani JA. Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer. 2005 AACR.
Hazra A, Ajani J, Wu T-T, Swisher S, Liao Z, Correa A, Liu J, Chiang S, Wu X. Chemotherapy Tailored to Fit: Genetic Variation in 5-FU Drug Action Pathway Modulates Therapeutic Response in Esophageal Cancer. UTMDACC, A Day of Science 2004.
Updated February 29, 2008